(3Z)-1-methyl-3-(pyridin-2-ylhydrazinylidene)indol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (3Z)-1-methyl-3-(pyridin-2-ylhydrazinylidene)indol-2-one
• 化学式: C₁₄H₁₂N₄O
• 分子量: 252.27
• InChiKey: XRLPLALGFARHCC-LGMDPLHJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Agents for reversing epigenetic silencing of genes
  申请人：The Johns Hopkins University

  公开号：US10227654B2

  公开（公告）日：2019-03-12

  The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.

  本发明提供了通过抑制甲基结合（MBD）蛋白与甲基化基因组 DNA 的相互作用，发现可有效逆转表观遗传沉默的制剂的方法。本发明还提供了重新激活具有 CpG 岛超甲基化的沉默基因的方法，以及治疗和预防癌症和镰状细胞性贫血等疾病的方法，方法是施用一种调节甲基结合域（MBD）蛋白介导的转录抑制的制剂，从而增加基因转录以预防或治疗疾病。此外，还提供了本发明确定的有助于治疗和预防癌症和镰状细胞性贫血等疾病的化合物。
• Agents for Reversing Epigenetic Silencing of Genes
  申请人：Nelson William G.

  公开号：US20100093768A1

  公开（公告）日：2010-04-15

  The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.
• AGENTS FOR REVERSING EPIGENETIC SILENCING OF GENES
  申请人：The Johns Hopkins University

  公开号：US20150252438A1

  公开（公告）日：2015-09-10

  The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.
• US9034574B2
  申请人：——

  公开号：US9034574B2

  公开（公告）日：2015-05-19
• [EN] AGENTS FOR REVERSING EPIGENETIC SILENCING OF GENES<br/>[FR] AGENTS DESTINÉS À INVERSER UN SILENÇAGE ÉPIGÉNÉTIQUE DE GÈNES
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2008083098A1

  公开（公告）日：2008-07-10

  [EN] The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.
  [FR] L'invention concerne des procédés permettant de découvrir des agents qui sont efficaces pour inverser un silençage épigénétique par inhibition de l'interaction de protéines de liaison au méthyle (MBD) avec un ADN génomique méthylé. L'invention concerne également des procédés destinés à réactiver des gènes silencieux présentant une hyperméthylation de l'îlot CpG. L'invention concerne également des procédés de traitement et de prévention de maladies, notamment le cancer et l'anémie dépranocytaire, consistant à administrer un agent qui régule la répression transcriptionnelle médiée par les protéines de liaison au méthyle (MBD), pour augmenter la transcription génétique afin de prévenir ou de traiter une maladie. En outre, les composés identifiés par l'invention sont utiles pour traiter et pour prévenir des maladies, notamment le cancer et l'anémie dépranocytaire.